image credit: Unsplash

Univercells Launches New Bioprocess Subsidiary

Univercells launched a new bioprocess subsidiary—Univercells Technologies—which will focus on the commercialization of the product portfolio and will explore new technology developments to expand its position in the cell and gene therapy market, according to Mathias Garny, general manager.

“With the scale-X™ bioreactor portfolio and the NevoLine™ biomanufacturing platform, designed and commercially validated by Univercells, the company experiences today a turning point,” he said. “The commercialization of these cutting-edge technologies under a dedicated brand will boost the expansion of our market reach to support advances in cell and gene therapy manufacturing.”

Read More on Genetic Engineering and Biotechnology News